The most interesting and notable prostate cancer research from the 2010 ASCO (American Society of Clinical Oncology) conference.
Held in Chicago June 4-8, the annual meeting brought together 50,000 physicians, researchers, and other health care professionals from around the globe to discuss and hear the latest results in cancer research. Click the links to read the articles on the ASCO website.
Data emerging from a large, randomized international trial suggest that continuous androgen deprivation plus external beam radiation therapy “should be the standard treatment approach” for men with locally advanced prostate cancer, according to participants from Sunday’s Genitourinary (Prostate) Cancer Oral Abstract Session.
Denosumab Superior to Zoledronic Acid for Delaying Skeletal Events in Prostate Cancer
In a large, randomly assigned, double-blind, active-controlled phase III trial of patients with castration-resistant prostate cancer (CRPC) that metastasized to bone, denosumab delayed the time to a skeletal- related event (SRE) by 3.6 months over zoledronic acid.